Inactive Instrument

PERRIGO Share Price TEL AVIV STOCK EXCHANGE

Equities

Pharmaceuticals

End-of-day quote TEL AVIV STOCK EXCHANGE
- ILa - Intraday chart for PERRIGO

Financials

Sales 2024 * 4.62B 1,701B 386B Sales 2025 * 4.83B 1,779B 403B Capitalization 3.47B 1,277B 290B
Net income 2024 * -73M -26.88B -6.09B Net income 2025 * 106M 39.04B 8.85B EV / Sales 2024 * 1.45 x
Net Debt 2024 * 3.21B 1,182B 268B Net Debt 2025 * 3.01B 1,109B 251B EV / Sales 2025 * 1.34 x
P/E ratio 2024 *
-17.5 x
P/E ratio 2025 *
159 x
Employees -
Yield 2024 *
4.33%
Yield 2025 *
4.61%
Free-Float 99.66%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 55 30/23/30
Director of Finance/CFO 49 16/22/16
Chief Tech/Sci/R&D Officer - 01/15/01
Members of the board TitleAgeSince
Chairman 55 15/20/15
Director/Board Member 68 06/17/06
Director/Board Member 67 06/17/06
More insiders
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.
More about the company